Oxford BioTherapeutics, a biopharmaceutical company developing a range of innovative antibody-drug conjugates or ADCs based on the company’s proprietary OGAP® targeting platform linked to novel antibody and cancer toxin technologies from leading companies around the world, and Berlin Chemie, a member of the Menarini Group, have designated a novel antibody-drug conjugate targeting Non-Hodgkin’s B-Cell Lymphoma and solid tumors, including some subsets of breast cancers, where the target is expressed, as the second clinical development candidate under the companies’ strategic oncology partnership. The ADC is currently undergoing formal regulatory enabling studies to support an application for the future clinical trial phase.

The ADC candidate is a novel antibody-based therapeutic against an undisclosed cancer target identified by OBT’s proprietary OGAP® discovery technology and has completed in vivo proof-of-concept in several solid and liquid tumour models and exploratory toxicology testing. The therapeutic incorporates proven ADC technology developed by ImmunoGen, and has successfully completed preclinical in vivo proof-of-concept and exploratory toxicology testing.

“[The initiation of] the second oncology programme in our partnership with the Menarini Group is a further strategic milestone for Oxford BioTherapeutics, as we continue to advance our cancer therapies to the clinic. We have combined proven ADC technologies with our world-class target discovery capabilities to build a pipeline of novel cancer therapeutics, and we look forward to progressing further programs into clinical development as part of our innovative alliance with Menarini.” noted Christian Rohlff, Chief Executive Officer of Oxford BioTherapeutics.


Commenting on the joint collaboration agreement, Andrew Slade, Chairman Menarini Biotech/Berlin-Chemie, said: “Berlin Chemie/Menarini Group has a long-standing commitment to advancing the treatment of cancer, and we look forward to accelerating our shared pipeline of novel antibody-based therapies into clinical development [which is part of with] our strategic oncology alliance with Oxford BioTherapeutics.”

Oxford BioTherapeutics and Berlin Chemie/Menarini Group established their strategic partnership in October 2012, covering the development and commercialization of five of OBT’s proprietary antibody-based cancer therapies. In October 2013, the companies designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical development candidate under the partnership. Under the collaboration, Menarini contributes clinical and manufacturing expertise, supported by an investment of up to $1 billion, and potential milestone payments of a similar magnitude plus royalties on future sales.

Published in: Menarini Group website